Growing Up with HIV: A Comprehensive Review of Treatment and Care in Low- and Middle-Income Countries.

IF 4.4 2区医学 Q2 INFECTIOUS DISEASES

Current HIV/AIDS Reports Pub Date : 2025-11-07 DOI:10.1007/s11904-025-00762-z

Brigid E O'Brien, Elizabeth Maidl, Jacob L Todd, Miriam Abadie, Moses Mugerwa, Katherine R Simon, Sarah Perry

{"title":"Growing Up with HIV: A Comprehensive Review of Treatment and Care in Low- and Middle-Income Countries.","authors":"Brigid E O'Brien, Elizabeth Maidl, Jacob L Todd, Miriam Abadie, Moses Mugerwa, Katherine R Simon, Sarah Perry","doi":"10.1007/s11904-025-00762-z","DOIUrl":null,"url":null,"abstract":"Purpose of review: Despite declining numbers of new pediatric HIV infections and advancements in treatment for children and adolescents living with HIV (CALHIV), barriers remain. Comprehensive care for CALHIV in low- and middle-income countries is challenged by limited treatment options, unique psychosocial challenges, and caregiver reliance. Successful care relies on understanding the unique developmental needs, as well as their vulnerabilities to treatment failure and HIV drug resistance.Recent findings: CALHIV lag behind adults in meeting global UNAIDS targets. Increasing availability of pediatric fixed dose combinations (FDC) of abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) may address some challenges but providing alternatives should be prioritized. Emerging evidence has demonstrated pre-treatment and acquired HIV drug resistance (HIVDR) are more prevalent in CALHIV. While novel therapies are in development, access remains a concern. Increased child and adolescent-friendly treatment options are needed to provide quality life-long comprehensive care to CALHIV in low- and middle-income countries (LMIC). Expanded research and access to novel therapies is key to close treatment gaps between CALHIV and their adult counterparts and address emerging HIV drug resistance.","PeriodicalId":10930,"journal":{"name":"Current HIV/AIDS Reports","volume":"22 1","pages":"52"},"PeriodicalIF":4.4000,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current HIV/AIDS Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11904-025-00762-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Despite declining numbers of new pediatric HIV infections and advancements in treatment for children and adolescents living with HIV (CALHIV), barriers remain. Comprehensive care for CALHIV in low- and middle-income countries is challenged by limited treatment options, unique psychosocial challenges, and caregiver reliance. Successful care relies on understanding the unique developmental needs, as well as their vulnerabilities to treatment failure and HIV drug resistance.

Recent findings: CALHIV lag behind adults in meeting global UNAIDS targets. Increasing availability of pediatric fixed dose combinations (FDC) of abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) may address some challenges but providing alternatives should be prioritized. Emerging evidence has demonstrated pre-treatment and acquired HIV drug resistance (HIVDR) are more prevalent in CALHIV. While novel therapies are in development, access remains a concern. Increased child and adolescent-friendly treatment options are needed to provide quality life-long comprehensive care to CALHIV in low- and middle-income countries (LMIC). Expanded research and access to novel therapies is key to close treatment gaps between CALHIV and their adult counterparts and address emerging HIV drug resistance.

查看原文本刊更多论文

与艾滋病毒一起成长：低收入和中等收入国家治疗和护理的全面审查。

综述目的：尽管儿童艾滋病毒新发感染数量下降，儿童和青少年艾滋病毒（CALHIV）治疗取得进展，但障碍仍然存在。低收入和中等收入国家对CALHIV的全面护理面临着治疗选择有限、独特的社会心理挑战和对护理人员的依赖等挑战。成功的护理依赖于了解独特的发展需求，以及他们对治疗失败和艾滋病毒耐药性的脆弱性。最近的发现：艾滋病毒在实现联合国艾滋病规划署全球目标方面落后于成年人。增加阿巴卡韦/拉米夫定/多替格拉韦（ABC/3TC/DTG）儿童固定剂量组合（FDC）的可用性可能会解决一些挑战，但应优先提供替代方案。新出现的证据表明，治疗前和获得性艾滋病毒耐药性（HIVDR）在CALHIV中更为普遍。虽然新的治疗方法正在开发中，但获取途径仍然是一个问题。需要增加对儿童和青少年友好的治疗选择，以便在低收入和中等收入国家（LMIC）为艾滋病毒感染者提供高质量的终身综合护理。扩大研究和获得新疗法是缩小CALHIV与成人HIV之间的治疗差距和解决新出现的HIV耐药性的关键。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current HIV/AIDS Reports INFECTIOUS DISEASES-

CiteScore

8.10

自引率

2.20%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of HIV/AIDS. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as antiretroviral therapies, behavioral aspects of management, and metabolic complications and comorbidity. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.